New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
07:16 EDTAGNAllergan price target raised to $107 from $83 at Piper Jaffray
Piper Jaffray raised its price target for Allergan (AGN) shares to $107 citing the issuance of patents on Restasis. Piper believes the recent valuation expansion of shares is justified but thinks additional expansion is unlikely given the paragraph IV litigation versus Actavis (ACT). The firm reiterates a Neutral rating on Allergan.
News For AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 21, 2015
12:30 EDTAGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 13, 2015
14:00 EDTAGNActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
07:39 EDTAGNAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use